FDA-Drug2026-04-22Class IICHEMICAL
Cipla USA Cinacalcet Hydrochloride 60 mg tablets recalled for elevated nitrosamine impurity
HEAVY METALSNationwide distribution
Stop taking Cipla Cinacalcet 60 mg tablets
Cipla USA is recalling specific lots of Cinacalcet Hydrochloride 60 mg tablets because they contain higher-than-acceptable levels of N-Nitroso Cinacalcet, a nitrosamine impurity. This impurity can pose a health risk with long-term exposure. The affected lots were distributed nationwide.
- Check if your Cinacalcet bottle matches one of these lot numbers: 4PB0215, 4PB0216, 4PB0515, 4PB0516, 4PB0517, or 5PB0167.
- Do not take tablets from affected lots.
- Contact your pharmacy or doctor immediately for a replacement or alternative medication.
- Do not throw away your medication; ask your pharmacist how to safely dispose of it.
Hazard
CGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limit
Sold states
Nationwide in the USA
Affected count
96,096 bottles
Manufactured in
10 Independence Blvd, N/A, Warren, NJ, United States
Products
Cinacalcet Hydrochloride Tablets, 60 mg, 30 Tablets per bottle, Rx Only, Manufactured by: Cipla Ltd., MIDC, Patalganga, India; Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059. NDC: 69097-411-02
Official notice
https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0450-2026More Cipla USA, Inc. recalls
- FDA-Drug2026-04-22Cipla Cinacalcet Hydrochloride 30 mg tablets recalled for elevated N-Nitroso impurity
- FDA-Drug2026-04-22Cipla cinacalcet 90 mg tablets recalled for elevated impurity levels
- FDA-Drug2026-04-15Cipla Lanreotide Injection 120 mg recalled for sterility assurance defect
- FDA-Drug2026-04-15Cipla Lanreotide Injection 120 mg recalled for sterility concerns
Don't want to check this manually?
We email you a Sunday digest of new federal recalls relevant to parents — free, no credit card. Or upgrade to as-it-happens alerts for the brands you actually own.
Get the Sunday Brief